公开(公告)号：US20220206015A1

公开(公告)日：2022-06-30

申请号：US17693789

申请日：2022-03-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk BLOCK ,  Hanspeter BRUNNER ,  Thomas DIETERLE ,  Ursula-Henrike WIENHUES-THELEN ,  Christian ZAUGG ,  Andre ZIEGLER

IPC: G01N33/68 ,  A61K31/40 ,  G01N33/62

Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

公开(公告)号：US20220034910A1

公开(公告)日：2022-02-03

申请号：US17403078

申请日：2021-08-16

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christian ZAUGG ,  Dirk BLOCK ,  Ursula-Henrike WIENHUES-THELEN ,  Hans-Peter BRUNNER ,  Friedemann KRAUSE ,  Fabian MODEL ,  Vincent ROLNY

IPC: G01N33/68

Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.